Literature DB >> 7530437

First trimester biochemical screening for trisomy 21: the role of free beta hCG, alpha fetoprotein and pregnancy associated plasma protein A.

K Spencer1, D A Aitken, J A Crossley, G McCaw, E Berry, R Anderson, J M Connor, J N Macri.   

Abstract

The potential efficacy of screening for trisomy 21 in the first trimester, using maternal serum markers alpha fetoprotein, free beta human chorionic gonadotropin, unconjugated oestriol and pregnancy associated plasma protein A, was studied in an unselected population of women between the seventh and fourteenth week of gestation. Using a combination of alpha fetoprotein and free beta human chorionic gonadotropin, 53% of affected pregnancies could be identified at a false positive rate of 5%. Unconjugated oestriol and pregnancy associated plasma protein A levels were lower in cases of trisomy 21, but their inclusion with other markers did not significantly improve detection rate. Monitoring the same pregnancies also in the second trimester showed that screening in the first trimester identified the same cases as in the second. We conclude that first trimester screening using free beta human chorionic gonadotropin and alpha fetoprotein, is a viable possibility and will lead to detection rates in excess of 50%. Prospective studies are needed to confirm these observations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7530437     DOI: 10.1177/000456329403100504

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  2 in total

1.  A Risk Model for Predicting Fetuses with Trisomy 21 Using Alpha-Fetoprotein Variants L2 Combined with Maternal Serum Biomarkers in Early Pregnancy.

Authors:  Yiming Chen; Bin Wu; Yijie Chen; Wenwen Ning; Huimin Zhang
Journal:  Reprod Sci       Date:  2021-11-08       Impact factor: 3.060

2.  [Prenatal diagnosis of trisomy 21 by fluorescence in situ hybridization (FISH): about the first tests in Morocco].

Authors:  Afaf Lamzouri; Abdelhafid Natiq; Mariam Tajir; Mohamed Sendid; Abdelaziz Sefiani
Journal:  Pan Afr Med J       Date:  2012-10-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.